Defining Subset-Wise Myeloid Responses To Immune Checkpoint Blockade In Melanoma

Immune checkpoint blockade (ICB) is associated with improved survival in patients with metastatic melanoma (MM). Despite this, many patients have limited clinical benefit, and there is ongoing attrition amongst responders. Moreover, ICB is associated with auto-immune toxicity. Peripheral biomarkers can help early identification of non-responders, as well as assist in treatment stratification. Recent evidence suggests that myeloid populations may play a role in modulating ICB response, but this has yet to be full defined at the transcriptomic level.